- Trials with a EudraCT protocol (87)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
87 result(s) found for: Oropharyngeal cancer.
Displaying page 1 of 5.
EudraCT Number: 2011-005165-21 | Sponsor Protocol Number: RMRCT0034 | Start Date*: 2012-01-30 | |||||||||||
Sponsor Name:University of Warwick | |||||||||||||
Full Title: De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oro... | |||||||||||||
Medical condition: Human Papillomavirus oropharyngeal squamous cell carcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002360-14 | Sponsor Protocol Number: AK-2016-HHC1 | Start Date*: 2016-09-29 | ||||||||||||||||||||||||||
Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET | ||||||||||||||||||||||||||||
Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer | ||||||||||||||||||||||||||||
Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001361-12 | Sponsor Protocol Number: FG001-CT-003 | Start Date*: 2022-08-25 | ||||||||||||||||
Sponsor Name:FluoGuide A/S | ||||||||||||||||||
Full Title: An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma | ||||||||||||||||||
Medical condition: Oral and oropharyngeal squamous cell carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003389-26 | Sponsor Protocol Number: RG14-093 | Start Date*: 2015-01-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer | |||||||||||||
Medical condition: Oropharyngeal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002244-16 | Sponsor Protocol Number: NRG-HN002 | Start Date*: 2016-09-12 | |||||||||||
Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland | |||||||||||||
Full Title: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | |||||||||||||
Medical condition: Locoregionally advanced oropharyngeal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003392-32 | Sponsor Protocol Number: 2014/VCC/0014 | Start Date*: 2014-10-24 | |||||||||||
Sponsor Name:Velindre NHS Trust | |||||||||||||
Full Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer | |||||||||||||
Medical condition: Oropharyngeal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003652-32 | Sponsor Protocol Number: ISA101b-OPC-03-19 | Start Date*: 2021-04-13 | |||||||||||
Sponsor Name:ISA Therapeutics B.V. | |||||||||||||
Full Title: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progres... | |||||||||||||
Medical condition: Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001077-87 | Sponsor Protocol Number: IJB-RT-HNC-001 | Start Date*: 2019-08-08 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t... | |||||||||||||
Medical condition: advanced head and neck cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002163-34 | Sponsor Protocol Number: TopROC | Start Date*: 2017-11-28 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC) | |||||||||||||
Medical condition: squamous cell carcinoma of the oropharynx | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004603-35 | Sponsor Protocol Number: REACH | Start Date*: 2009-04-28 | |||||||||||||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||||||||||||
Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study | |||||||||||||||||||||||
Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001354-41 | Sponsor Protocol Number: UCLONCO08-001 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study | ||||||||||||||||||||||||||||
Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002187-25 | Sponsor Protocol Number: Accrobat | Start Date*: 2007-01-26 |
Sponsor Name:Radiumhemmet, Karolinska University Hospital | ||
Full Title: A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unr... | ||
Medical condition: Patient with locally advanced non-resectable squamous cell carcinoma of the head and neck stage III or IV, oral, oropharyngeal, laryngeal or hypopharyngeal cancer, non-resectable. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002799-28 | Sponsor Protocol Number: TG4001.12 | Start Date*: 2020-03-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Transgene | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of the he... | ||||||||||||||||||||||||||||||||||||||
Medical condition: HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004277-31 | Sponsor Protocol Number: E012-HPV | Start Date*: 2021-12-23 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:eTheRNA immunotherapies NV | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Incurable recurrent or metastatic (R/M) HPV16-positive (HPV16+) tumors (e.g. oropharyngeal cancer, cervical, vulvar, vaginal, anal, penile cancer, etc.) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) NL (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003856-19 | Sponsor Protocol Number: CVB2018-2 | Start Date*: 2019-01-09 | |||||||||||
Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK | |||||||||||||
Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients | |||||||||||||
Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000308-13 | Sponsor Protocol Number: 1740-HNCG | Start Date*: 2019-08-30 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab an... | |||||||||||||
Medical condition: Oropharyngeal Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004349-29 | Sponsor Protocol Number: 01-10-2014 | Start Date*: 2015-04-01 | ||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||
Full Title: Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients | ||||||||||||||||||
Medical condition: The study will include participants with xerostomi (International Classification of Diseases-10: DQ 838A) and oropharyngeal cancer (DC 10). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003934-25 | Sponsor Protocol Number: 3475-412 | Start Date*: 2017-03-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous... | |||||||||||||
Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021658-21 | Sponsor Protocol Number: HN10/01 | Start Date*: 2010-09-27 |
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||
Full Title: Phase II study of preoperative TPF chemotherapy in locally advanced resectable oral cavity squamous cell cancer in order to improve the rate of pathological complete response | ||
Medical condition: oral cavity cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
